Granulocyte-macrophage colony-stimulating factor (GM-CSF) counteracts the inhibiting effect of monocytes on natural killer (NK) cells by Bosch, G.J.M. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/22130
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Clin Exp Immunol 1995; 101:515 -520
Granulocyte-macrophage colony-stimulating factor (GM-CSF) counteracts 
the inhibiting effect of monocytes on natural killer (NK) cells
G. VAN D E N  BO SCH , F. P R E IJE R S , A. V R E U G D E N H IL , J. H E N D R IK S * , F. MAAS & T. DE W IT T E
Division o f  Haematology, Department o f  Internal Medicine, and * Department o f  Medical Statistics. University Hospital Nijmegen,
Nijmegen, The Netherlands
(Accepted for publication 12 May 1995)
SU M M A R Y
GM-CSF is known to accelerate haematopoietic recovery following allogeneic bone marrow 
transplantation (BMT). In addition, it may restore and enhance both granulocyte and monocyte 
functions. Stimulation of monocyte functions may induce a direct or an indirect anti-Ieukaemie 
activity due to an increase of cellular cytotoxicity and production of cytokines which may result in 
a reduction of the relapse rate after BMT. NK cells may play a crucial role in this activity, 
Therefore we studied the influence of monocytes on N K  activity in combination with GM-CSF, 
Lymphocytes and monocytes were isolated from bufTy coats of healthy individuals by counterflow 
centrifugation élutriation (CCE). N K  activity was exerted by CD3“ CD56+ cell populations and 
could be enhanced by IL-2 incubation overnight. Incubation of CD3“ CD56H cells with GM-CSF 
in the presence or absence of IL-2 hardly influenced N K  activity of the lymphocyte population. 
Low amounts of monocytes enhanced NK activity. N K  activity in lymphocyte population in the 
presence of equivalent numbers of monocytes with or without IL-2 was strongly decreased 
irrespective of the effector:target ratio (ETR). This appeared not to result from sterical hindrance 
effects of the present number of cells. However, addition of GM-CSF abrogated the inhibition of 
NK activity by monocytes in the presence of IL-2. In monocyte fractions neither IL-2 nor GM- 
CSF yielded NK activity. Our findings indicate that GM-CSF can affect NK activity by counter­
acting the suppressing effects of monocytes, and hence may improve the outcome after BMT.
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IN T R O D U C T IO N
Allogeneic bone marrow transplantation (BMT) is at present 
the most effective treatment of patients with leukaemia, though 
long-term survival is still not optimal [1,2]. The major compli­
cations influencing treatment outcome, such as graft-vmm- 
host disease (GVHD), opportunistic infections due to a 
prolonged neutropenic phase, and relapse of the underlying 
malignancy after BMT, still account for significant morbidity 
and mortality. GVHD can be successfully prevented by partial 
T cell depletion from the transplant [3] or immunoprophylaxis 
with cyclosporin-A and methotrexate [4].
Haematopoietic growth factors have been shown to shorten 
the neutropenic period [5]. GM-CSF also stimulates particular 
effector functions of mature granulocytes and macrophages [6].
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In vitro studies have shown that GM-CSF can increase 
antibody-dependent and independent cellular cytotoxicity 
(ADCC) [7-10] mediated by monocytes directed against 
tumour cell lines [11]. In a prospective randomized study 
among BMT recipients [12], GM-CSF administration was 
associated with a reduced relapse rate suggesting an improve­
ment of anti-leukaemic activity,
Sever a I re po r ts h a ve s h own th a t G M - CS F ca n a (fee l pa rti- 
eular T lymphocyte cytotoxic functions in vitro [13,14]. In 
addition, a synergistic effect of GM-CSF with IL-2 resulting 
in a more pronouneed cytotoxici ty of T 1 ymphocytes and NK 
cells has been described [15], These data suggested that GM- 
CSF may also enhance anti-leukaemic activity mediated by 
lymphocytes. However, monocytes appeared to up- or down- 
regulate NK activity depending on their functional state and 
concentration [16,17],
We studied the effect of GM-CSF on the anti-leukaemic 
activity mediated by NK cells and monocytes. We found that 
GM-CSF did not enhance anti-leukaemic activity in monocytes 
directly, but counteracted the inhibiting effect of monocytes on 
NK cells, resulting in an enhanced anti-leukaemic activity.
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M A T E R IA L S  AND M E T H O D S
Isolation o f  monocytes and lymphocytes 
Mononuclear cells were separated from peripheral blood bufFy 
coats of live healthy volunteers by Percoli l ’075g/ml (Pharma­
cia, Uppsala, Sweden) and centrifugated at 500 g/min for 
20 min.
Separation of monocytes and lymphocytes from mono­
nuclear cells was performed by cell-scatter-monitored counter­
flow centrifugation élutriation (CCE), using a Curamé-3000, 
four-chamber-rotor (Dijkstra bv, Alkmaar, The Netherlands) 
as described previously [18,19], Different cell fractions were 
collected by reducing the rotor speed from 3000 to 2000 rev/m in 
with a constant How rate of 12ml/min (Fig. 1), Purification was 
assessed by morphological analysis of M ay-Grünw ald- 
Giemsa (MGG)-stained cytospin samples. Viability was deter­
mined by trypan blue dye exclusion,
CD56 (Leu-19; Becton Dickinson). CD3 CD56 + was consid­
ered as NK population. Staining was performed using a 
standard method. Briefly, 100 //I of different CCE cell fractions 
were incubated at 4°C for 15 min with the appropriate volume 
of PE- and FITC-conjugated MoAbs. Remaining erythrocytes 
were subsequently lysed by FACS lysing reagent (Becton 
Dickinson) for 10 min at room temperature. After lysis, cells 
were washed once with PBS and flow cytometrically analysed.
Cytotoxicity
Lymphocytes, monocytes or combinations of both were incu­
bated with or without 500U/ml recombinant 1L-2 (Glaxo, 
Geneva, Switzerland) and with or without 250 ng/ml recombi­
nant GM-CSF (GM-CSF; Sandoz Pharma Ltd, Basel, Switzer­
land) in a final volume of 1 '0 ml culture medium in a humidified 
incubator with 5% CO2 in air at 37°C. In control experiments 
beads with a diameter of 10/ini (DNA Check; Coulter) were 
mixed with lymphocytes. After 18 h of incubation* supernatants 
were removed. Cells were resuspended in culture medium and 
used as effector cells in a 51Cr-release assay.
In order to determine the NK activity and IL-2-induced 
cytotoxicity a 51Cr-release assay was used with cell line K562 as 
target. K562 was maintained in logarithmic growth phase in 
culture medium in a humidified incubator with 5% CO2 in air 
at 37°C, Briefly, 2 x 106 target cells were labelled with 100/zCi 
51Cr (NaCrO^ Amersham, Aylesbury, UK) at 37°C for Ih. 
After incubation, cells were washed three times with GPBS and 
suspended in culture medium. One hundred microlitres 51Cr- 
labelled target cells (1 x 104) were incubated with 100/¿I effector 
cells in different ratios (6*25, 12*5, 25 and 50) in 96-well U- 
bottomed plates (Costar, Cambridge, MA) at 37°C for 3*5 h. 
Subsequently* plates were centrifuged and 100/d supernatant 
from each well were collected. Radioactivity was determined 111 
a LKB gamma counter. Percentage of specific 51Cr release was 
calculated using the following formula: Percentage 5lCr release 
™ (experimental51 Cr release-spontaneous 51Cr release)/(total 
51Cr release-spontaneous 51Cr release), where the spontaneous 
51 Cr release represents the release of target cells as such. The 
£  |
total Cr release was determined in cell suspensions of target 
cells treated with 10 /¿I zap-oglobin (Coulter Electronics Ltd, 
Luton, UK).
I  mm unoph en 0 typ ing o f  N K  effe c / ors
Immunophenotypic expression of the cytotoxic effector cell 
population was assessed by determination of the cytotoxicity 
of the MoAb in combination with RC. Cells (5 x 106/ml) were 
incubated in culture medium with 10/xg/ml MoAb in the 
presence of 1:4 v/v RC for lh . Subsequently, cells were 
washed, resuspended in culture medium and incubated in the 
presence of 500U/ml IL-2 for 18 h to enhance NK activity. 
Thereafter cytotoxicity was determined in a 51Cr-release assay 
as described, using the initial cell count in order to test the 
original number of cells that were responsible for NK activity.
Statistical analysis
Due to biological variation between different donor samples, 
percentage of specific 51Cr release was log-transformed in order 
to equalize the variances of the measurement error at different 
levels of the percentage of 51Cr release (i.e. to improve homo- 
scedasticity).
To improve the fit of this linear model against the effector:
Monoclonal antibodies and complement 
The following lgG 2a isotype-expressing and rabbit comple­
ment (RC)-iixing murine MoAbs were used: CD3 (WT32); 
CD7 (WT1); CD8 (WT 82) kindly provided by Dr W. Tax 
(Department of Nephrology, University Hospital Nijmegen, 
The Netherlands); CD4 (OKT4), purchased from American 
Type Culture Collection (ATCC, Rockville, MD) cell bank; 
CD2 (Leu-5b); CD 16 (Leu-1 lc) and CD56 (Leu-19) purchased 
from Becton Dickinson (Mountain View, CA). MoAbs were 
purified by using Staphylococcus aureus protein A coupled to 
Sepharose (Pharmacia Biosystems BV, Woerden, The Nether­
lands). Sera of 4-6-week-old New Zealand white rabbits were 
used as RC source. Sera of all rabbits were tested separately for 
specific and non-specific lysis of mouse spleen cells and human 
T cell lines. Sera with optimal cytotoxicity were pooled, snap 
frozen and stored at -70°C  until use.
Adherence o f  monocytes
Cells from lymphocyte fractions that were contaminated with 
monocytes (2200-2150 rev/mi n fractions; Fig. 1) were washed 
twice with glucose PBS (GPBS) and resuspended (2 x 106 cells/ 
ml) in culture medium containing RPMI 1640 medium (Flow 
Labs* Irvine» UK) supplemented with 10% fetal calf serum 
(FCS), 2mM L-glutamine (Flow Labs), lOOU/ml penicillin and
10 jug/m! streptomycin (Flow Labs) in plastic tissue culture 
flasks and incubated in a humidified atmosphere of 5% C 0 2 
in air at 37°C for 1 h in order to allow monocytes to adhere.
Afterwards, non-adherent cells were harvested by gently 
pipetting. The non-adherent cell population contained > 99% 
lymphocytes as determined in cytospin centrifuge preparations 
after MGG staining, with a viability >98% . The remaining 
adherent cells were incubated at 4°C during 30min and washed 
three times with GPBS. The adherent cell population contained 
> 85% monocytes, with a viability >95% . The adherent and 
non-adherent cells were resuspended (5 x 106 cells/ml) in cul­
ture medium and directly used as effector populations in 51Cr- 
release assay.
Phenotypic analysis o f  lymphocyte suhpopulations 
Lymphocyte subpopulations were characterized by flow cyto­
metric immunofluorescence analysis (Coulter Epics Elite; Coul­
ter Corporation, Hialeah* FL) using FITC-conjugated CD3 
(UCHT1; Dakopatts, Glostrup, Denmark) and PE-conjugated
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target ratio (ETR), the regression of the log (51Cr release) versus 
redoubling of the ETR (log2 (ETR/6-25)) was studied. The 
influences of monocytes and GM-CSF in presence or absence 
of IL-2, separately, on the increase of log (5lCr release) were 
determined in an analysis of covariance. Therefore the ETR of 
12*5 was used as representative value to compare the other 
respective ETRs, The addition of monocytes and GM-CSF was 
tested as independent class variables. Using these models the 
log-transformed 51Cr-release was related to the ETR as follows;
■— I'M«# (hTR/6 ■ 25)
where ETR ranges from 6-25 to 50, m and g  indicate monocyte 
and GM-CSF, respectively, ¡3 indicates the increase of the log 
(5ICr release) per doubling of the ETR, and//, indicates the log 
(5lCr release) at ETR of 12*5,
100
R E SU L T S
Evaluai ion o f  élutriation fractions
Mononuclear cells of five donors were isolated by CCE. The 
evaluation of the cell number of each fraction (2850- 2000 rev/ 
min) and the percentage of T cells and NK cells determined, 
using flow cytometric immunofluorescence analysis, is shown in 
Fig, 1. Almost all lymphocytes were recovered in the rotor 
speed fractions down to 2150 rev/min, whereas most monocytes 
were eluted thereafter, Fractions that contained >95% mono­
cytes (2100 and 2000 rev/min) were collected and used as
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Fig. 1. The absolute number of nucleated cells ( • ) ,  determined by cell 
counting, and the percentage of lymphocytes (■) and monocytes (▼) by 
morphological analysis, in the different fractions of counterflow cen­
trifugation élutriation (CCE) of five donors. The lymphocyte subpopu­
lations of T cells (CD3 1 expression; A) and NK cells (CD3 C D 561 
expression; □) in each fraction were analysed by flow cytometric 
¡mm uno fluoresce nee, Fraction 2650 to 2300 rev/min were collected as 
lymphocyte fractions and fractions 2100 and 2000 rev/min as monocyte 
fractions.
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Fig. 2, 51 Cr release by the e flee tor cell population after incubation with 
MoAbs CD3 (A), CD4 (□}, CD8 (O), CD2 (V), CD7 (▼), CD 16 (A) 
and CD56 (♦) in combination with rabbit complement (RC) or without 
any addition (■) for I h is plotted for di fie rent effector: target ratios 
(ETRs). Cell line K562 was used as target, One out o f  three represen­
tative experiments is shown.
monocyte fraction. Fractions that consisted of > 95% lympho­
cytes (2650-2300rev/min) were collected. This lymphocyte 
fraction contained 58% CD3* cells and 26% N K  cells.
Imnnmophenotypic analysis o f  the cytotoxic effector population 
The remaining N K  activity after elimination of varying sub-
£  I
populations was determined in a Cr-release assay (Fig. 2). 
Pre-incubation with RC only did not influence NK activity 
(data not shown). Elimination of celts by CD3, CD4 and CD8 
did not influence NK activity. Elimination of CD7, C D I6 and 
CD56 resulted in a strong reduction, whereas CD2 partly 
inhibited NK activity. These results showed that the effector 
cells consisted of CD3 CD56 1 cells, which also express CD7, 
CD 16 and partly CD2.
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Fig. 3. (a) NK activity was determined in the lymphocyte fraction in the 
absence (■) or presence of equal (▼) or 1 : 10 (O) amounts o f  mono­
cytes. Inert beads were added to the lymphocyte fraction as control (A). 
NK activity in the added monocyte population was negligible (□). (b) 
NK activity in counterflow centrifugation élutriation (CCE) fraction 
2200-2150 rev/min (A) was compared with the activity of monocyte 
depletion ( ! )  and after adding back monocytes to the remaining 
lymphocytes (lymphocytes ; monocytes -  1:1; ▼ ). M o n o cy tes a s 
such were used as control (□). Cells were incubated in the presence of 
500tJ/ml IL-2 to enhance NK activity and determined in a 51 Cr-release 
assay. One out o f  three representative experiments is shown. ETR, 
Effector : target ratio.
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Monocyte : lymphocyte ratio effect on N K  activity 
NK activity was determined in lymphocytes from the lymph tv 
cyte fraction which are described in Fig. 1. Results of one 
representative experiment out of three are shown in Fig. 3a. 
Addition o f equivalent amounts o f monocytes resulted in a 
strong inhibition of N K  activity to K562. Addition of lower 
numbers of monocytes ( 1: 10) did not suppress but rather 
stimulated N K  activity. To show that the inhibiting effect was 
not induced by sterical hindrance by the presence of the high 
number of cells, equivalent amounts of inert beads of the same 
size as monocytes were mixed with lymphocytes. NK activity 
was slightly inhibited. These experiments were also repeated in 
the presence of four-fold excess of erythrocytes from the 
lymphocyte donor. No inhibition of NK activity was found 
(data not shown),
In order to study whether this suppressing effect was 
artificially induced by adding monocytes, NK activity was 
determined in CCE fraction 2200-2150 rev/min that contained 
substantial amounts of monocytes (monocyte : lymphocyte 
ratio of 1 : 1) before and after removing the monocytes by 
adherence to plastic (Fig. 3b). Adherence resulted in a five­
fold reduction of monocytes. The remaining fraction showed a 
significant increase of N K  activity which was comparable to 
the NK activity of lymphocyte fractions without detectable 
levels of monocytes (Fig. 3a). Addition of equal amounts of
Table 1. Results of the linear model of the log-transformed MCr release
-  IL-2
Monocytes GM-CSF Log5,Cr release* (s.e.m.) ft (s.e.m.)
— 3-404“ (0-082) 0-451 (0-074)
— + 3-488" (0-041) 0-408 (0-070)
+ — 3-054 (0-082) 0-373 (0-070)
+ 3-0901’ (0-082) 0-348 (0-070)
*** »,' « «. »i 4 . . . .  .... ...
+ IL-2
4-022" (0-144) 0-280 (0*123)
+ 4-054" (0-144) 0*262 (0*123)
+ — 3-370*’ (0-144) 0*267 (0*123)
+ 3-884" (0-144) 0*260 (0*123)
-K Without or with addition of monocytes and GM-CSF, 
respectively.
♦Log-transformed percentage of 51 Cr release at an effector: target 
ratio of 12*5.
p, Regression coefficient of the increase of the log-transformed 51 Cr 
release.
a,b Different letter indicates significant difference within the group in 
the absence or presence of IL-2.
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Fig. 4. NK activity was determined in the absence (a) and presence (b) 
o f  IL-2 (// = 5). Lymphocytes from fractions 2650-2300 rcv/min were 
incubated without GM-CSF (D,A) or with GM-CSF (■,▼) in the 
absence (□ ,■) or presence (A ,? ) of equal amounts o f  monocytes for 
!8 h. ETR, Effector: target ratio.
monocytes to the depleted lymphocyte population reintroduced 
the inhibiting effect.
Influence o f GM-CSF on inhibitory effect o f  monocytes on NK
activity*-
As an extension of the results of the previous experiments we 
studied the influence of GM-CSF on suppression of NK 
activity in the lymphocyte fraction in the presence as well as 
the absence of monocytes and IL-2. The mean and standard 
error of log-transformed data of five donors for the different 
ETR levels are depicted in Fig. 4.
Overall analysis of NK activity showed that the effect of 
GM-CSF was significantly different in the presence and absence 
of IL-2. Therefore the influence of GM-CSF on log (MCr 
release) under different conditions of monocytes was studied 
with or without IL-2 separately. Changes in ETR affected íog- 
trans formed values less in the presence than in the absence of 
IL-2 which was expressed by lower regression coefficients (/&; 
Table 1). The differences in these regression coefficients were 
not statistically significant in the presence or absence of IL-2, 
indicating that increase in NK activity with increasing ETR is 
comparable for each combination of additions.
Addition of monocytes with or without IL-2 inhibited NK 
activity significantly (P < 0*05) irrespective of the ETR (Fig, 4). 
Addition of GM-CSF in the absence of monocytes did not 
significantly influence NK activity. Without IL-2 the inhibiting 
effect of NK activity by monocytes was also not a (fee ted. 
However, in the presence of IL-2, GM-CSF abrogated the 
inhibiting effect of monocytes significantly (P < 0*05), resulting 
in a NK activity level as achieved with the lymphocyte fraction 
alone. Only one donor did not completely restore this suppres­
sive activity. Purified monocytes showed < 10% N K  activity in 
all combinations (data not shown).
(< :) 1995 Blackwell Science Ltd, Clinical and Experimenta! Immunology, 101:515 520
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D IS C U S S IO N
Treatment of bone marrow allograft recipients with GM-CSF 
has been shown to shorten the neutropenic phase, resulting in a 
lower incidence of infections after BMT [3]. Moreover, GM- 
CSF appeared to exert a graft versus leukaemia activity (GVL), 
since the relapse rate was lower in GM-CSF-treated recipients 
[12]. The mechanism behind this enhancement of GVL activity 
is at present not completely understood.
In allograft recipients GM-CSF induces a strong increase in 
the number of monocytes which may possess anti-leukaemic 
activity [20]. Previous studies have shown the influence of GM- 
CSF in regulating monocyte activity against tumour cell lines 
[21] and against leukaemia target cells [22], Moreover, in vitro 
experiments revealed that GM-CSF enhances ADCC by gran­
ulocytes [8], monocytes [7,9,10] and lymphocytes [33,35], 
Although T lymphocytes appeared not to express receptors 
for GM-CSF, some studies suggested that GM-CSF also 
potentiates proliferation of lymphocytes upon IL-2 stimulation 
[34] and their cytotoxic activity [35].
Okamura et a l  [13] showed that NK activity was signifi­
cantly enhanced by GM-CSF in the presence of IL-2. This 
enhancement could be an indirect effect by interferon-gamma 
(IFN-7 ), which was produced as a result of monocyte stimula­
tion, that activates the cytotoxic activity of NK cells.
In the present study we examined in vitro the influence of 
GM-CSF on monocytes and NK cells with regard to the 
induction of NK activity. NK cells are tumoricidal, and their 
cancer-related cytotoxic potential is augmented after activation 
with IL-2 [23,24]. Monocytes are able to down-regulate these 
IL-2-stimulated cells, depending on their functional state 
[25,26]. Monocytes were obtained by Percoll gradient centrifu­
gation followed by CCE [19], This method allows one to obtain 
highly purified monocytes that are not stimulated by the 
separation technique as such. These monocytes did not show 
cytotoxicity in the added concentrations against the NK-sensi- 
tive cell line K 562, even in the presence of GM-CSF. This may 
be due to the resting stage of these monocytes, in contrast to 
monocytes obtained by the usually applied Ficoll gradient 
centrifugation and adherence to plastic.
Lymphocyte fractions of CCE were used as the source of 
NK cells. Characterization of these fractions showed that the 
cells responsible for NK activity expressed CD2, CD7» CD56, 
and were CD3 . We found that addition of high amounts of 
monocytes to lymphocytes inhibited NK activity in the pre­
sence and absence of IL-2. Addition of comparable amounts of 
inert beads showed only a slight inhibition. Depletion oPT cells 
from the lymphocyte population did not decrease NIC activity. 
These results suggested that the inhibiting effect was induced 
by a direct functional effect of monocytes, in the used 
concentration.
This inhibition by monocytes was observed previously by 
other groups [27,28] using lower amounts of monocytes. How­
ever, these monocyte populations were stimulated with lipopo­
lysaccharide (LPS) before addition to the target population. 
The discrepancy with our findings can be explained by the high 
amounts of monocytes we used in our experiments. These 
monocyte fractions are expected to contain a small number of 
cells already stimulated in vivo before isolation. In our hands 
small numbers of monocytes did not inhibit but rather stimu­
lated NK activity. Although present data are controversial,
prostaglandin E2 (PGE2) appears to be involved in the inhibit­
ing effect of monocytes [29-31], and the functional balance 
between IL-1 [31] and PGE2 determines whether suppression or 
augmentation of NK activity is involved.
GM-CSF hardly influenced NK activity both in the pre­
sence and absence of monocytes. However, addition of GM- 
CSF in the presence ofIL-2 abrogated completely the suppres­
sive effect of monocytes 011 NK activity in almost all donors. I11 
one donor this abrogation appeared to be partial. This may be 
explained by a higher number of monocytes that could be 
stimulated in vivo before isolation. These results suggest that 
the anti-leukaemic activity in BMT recipients who are treated 
with GM-CSF may be enhanced by the abrogation of the 
suppressive activity of monocytes rather than by direct stimu­
lation of the monocytes.
In conclusion, GM-CSF does not directly influence NK 
cells, but indirectly affects NK activity by reversing the sup­
pressive activity of monocytes on NK activity against (or killing 
of) the NK-sensitive cell line K562.
These data suggest that NK activity and anti-leukaemic 
effects may be impaired in vivo by the recovery of monocytes 
following BMT. Preliminary data in an ongoing clinical trial 
demonstrated that patients treated with GM-CSF for 3 months 
showed no significant difference in monocyte: lymphocyte 
ratios [32]. These ratios were higher than 1 up to 2 months 
after BMT. Thus, it may be speculated that GM-CSF, in 
addition to accelerating monocyte recovery, potentially enhan­
cing cellular cytotoxicity and cytokine release, restores NK 
activity and hence improves the outcome after BMT. A large 
clinical trial is required, however, to prove this hypothesis. The 
precise mechanism by which GM -CSF affects NK activity 
remains to be elucidated.
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